NCG-HLA-A2.1 Mouse

NCG-HLA-A2.1 is a triple-immunodeficient NCG mouse expressing HLA-A*02:01. Human leukocyte antigens (HLA) is a major histocompatibility complex (MHC) antigen specific to humans and HLA-A is one of three major types of class I cell surface receptors. MHC class I receptors are expressed on all nucleated cells and are responsible for antigen presentation, CD8+ T cell maturation and cytotoxic T cell recognition.OriginThe NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain to express HLA-A2.1 creating the NCG-HLA.A2.1. The strain was transferred to Charles River in 2022.Stay Current with Our Expanding Triple-Immunodeficient Mouse Models PortfolioBe first to learn about additional new models coming soon and sign up to receive preordering information.   Sign up today